Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied.

Int J Mol Sci · 2025 · PMC12346542 · PMID 40806326

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

sunitinib but did not reach statistical significance; that PFS was longer (13.9 months vs. 8.5 months) [ 50 ] seems to be the result of the clinical trial CheckMate 9ER, which compared the combination of nivolumab with cabozantinib to sunitinib in a population of previously untreated 651 patients with advanced renal cell carcinoma.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.